Philip Morris International Inc. News
Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HBLENDS, EETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, SENTIA, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe and Sampoerna A in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 73 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in Stamford, Connecticut.
see morePhilip Morris International Inc. Market News
21h
Philip Morris International's $1.2 Billion Investment in Colorado Boosts Zyn Production
- Philip Morris International invests $1.2B in Colorado for Zyn production.
6d
Philip Morris International Reports Record Q2 Earnings, Stock Hits New High
Philip Morris International's Q2 earnings surpass expectations, driving stock to new highs.
13d
FDA's Approval of ZYN Nicotine Pouches Signals New Era for Philip Morris International
FDA grants modified risk status to Philip Morris's ZYN nicotine pouches.
20d
Philip Morris International's ZYN Nicotine Pouches Receive FDA's Modified Risk Order
FDA grants modified risk status to PMI's ZYN nicotine pouches, marking a significant milestone.
25d
FDA Approves ZYN Nicotine Pouches as Reduced-Risk Product, Impacting Philip Morris International
FDA approves ZYN as reduced-risk product, boosting Philip Morris stock.
05 May at 14:42
Philip Morris Q1 Beat FDA Delays Pressure PM Drop!
Philip Morris reported a stronger-than-expected Q1 with solid smoke‑free growth and reaffirmed full‑year guidance, but FDA review delays for nicotine‑pouch products and notable insider selling weighed on PM stock, causing a near 5% pullback. The company maintains a steady dividend and a dual revenue engine of high‑margin smoke‑free offerings plus cigarette pricing power.
28 Apr at 14:42
PM Stock Falls on FDA Delay, Japan Tax Headwinds!!
Philip Morris (PM) slid nearly 5% after reports of FDA slowdowns on nicotine-pouch approvals and fresh Japan tobacco taxes. Despite short-term technical weakness and regulatory pressure, analyst ratings remain largely positive with meaningful upside in price targets. Investors should monitor approval timelines, regional tax developments, and upcoming earnings for clarity.